Ex-Dividend Reminder: AbbVie, Dime Community Bancshares and MidWestOne Financial Group

AbbVie (ABBV), Dime Community Bancshares (DCOM) and MidWestOne Financial (MOFG) go ex-dividend on 1/16/2026; AbbVie will pay $1.73 on 2/17/26, Dime Community $0.25 on 1/23/26 and MidWestOne $0.2425 on 1/30/26. Based on ABBV's recent price of $220.75 the ABBV dividend implies a ~0.78% one-day adjustment (DCOM ~0.84%, MOFG ~0.60%), and annualized yields are cited at 3.13% (ABBV), 3.36% (DCOM) and 2.42% (MOFG). Intraday price moves were minor (ABBV +0.3%, DCOM -0.2%, MOFG +0.6%), and the note highlights that ex-dividend openings should reflect roughly the dividend amounts, all else equal.

Analysis

Market structure: Ex-dividend mechanics here are localized flow events — ABBV (yield ~3.13% on $220.75), DCOM (~3.36%) and MOFG (~2.42%) will see mechanical price drops (ABBV ~0.78%) on 1/16/26, briefly transferring cash from equity to holders. Large-cap defensive healthcare (ABBV) benefits from steady income-seeking demand; small regional banks (DCOM, MOFG) face mixed flows as deposit sensitivity and NII outlook compress relative value, pressuring regional multiples by several percent near-term. Cross-asset: modest rebalancing into cash/fixed income occurs for dividend recipients; options short-dated implied vols may rise around ex-div dates and earnings/FDA catalysts, creating cheap short-gamma opportunities.

Risk assessment: Tail risks include AbbV pipeline/regulatory shocks (FDA decisions, patent litigation) that can wipe >20% quickly and regional bank deposit runs or sudden NII swings that could halve expected payouts under a 3–6 month stress scenario. Immediate (days) effects are the ex-div mechanical drop; short-term (weeks) is volatility around earnings/FDA; long-term (quarters+) depends on drug approvals for ABBV and net interest margin normalization for banks. Hidden dependencies: dividend capture strategies and option pinning can distort order flow; tax regimes and institutional rebalancing at quarter-end (Mar/Jun/Sep/Dec) can amplify moves.

Trade implications: For ABBV, incremental long exposure makes sense around the ex-div gap — target 2–3% portfolio weight, add on pullbacks to >10% drawdown, and monetise into positive clinical/earnings beats within 3–6 months. Avoid dividend-capture on DCOM/MOFG; prefer selective long only if liquidity and credit metrics validate — otherwise underweight regionals by 1–2% and use pair trades (long large cap banks vs short small regionals) to isolate NII/loss risk. Use option structures: sell 30–45d covered calls on ABBV 2–4% OTM to lift yield or buy 3-month puts on MOFG 10% OTM as a low-cost hedge (max sizing 0.25–0.5% portfolio).

Contrarian angles: Consensus treats ABBV as safe yield; market may underprice binary upside from a successful mid-stage trial — a 10–20% positive re-rate is plausible within 3–6 months, so asymmetric long exposure is attractive. Conversely, small banks’ apparent safe yields ignore deposit stickiness risk and CRE exposure — short MOFG vs long JPM (dollar-neutral, target 6–12 week horizon) captures dispersion if NIM compresses. Watch implied vol and options flow around ex-div/earnings — elevated put buying on regionals would be a contrarian buy signal only if accompanied by deposit metrics stabilizing.

Key Decisions for Investors

• Establish a 2–3% portfolio position in ABBV around the ex-div gap (buy post-ex-div if price drops ~0.8% or more); use a 10% stop-loss and plan to hold 3–6 months to capture potential pipeline/earnings re-rating and 3.13% yield.
• Do NOT pursue dividend-capture on DCOM; instead, consider a conservative entry only if price weakness >8% post-ex-div and local credit metrics (loan/deposit ratio, NPLs) are stable — position size max 0.5–1% and target 12–24% upside in 3–6 months or cut at 8% loss.
• Reduce aggregate exposure to small regional banks (including MOFG) by 1–2% weight; initiate a dollar-neutral pair: short MOFG (size 1%) vs long JPM (size 1%) with a 6–12 week horizon to express NIM/credit dispersion risk.
• Options: sell 30–45d covered calls on ABBV ~2–4% OTM to boost yield (limit covered-call allocation to 1–2% portfolio) or sell cash-secured puts 3–5% below market to accumulate; buy 3-month MOFG puts 10% OTM as a hedge-sized no more than 0.25% of portfolio to protect against deposit-run tail risk.